Zhejiang Conba Pharmaceutical (600572) announced on the evening of August 29 that the National Medical Products Administration recently issued the "Notice on Traditional Chinese Medicine Protected Varieties (Extended Protection Period No. 16)" approving the continued second-level protection of the "Zhixinzhen" Musk Attentive Pill produced by the company's wholly-owned subsidiary in Inner Mongolia, Zhejiang Conba Pharmaceutical. This pharmaceutical is used for stable angina and effort-associated angina of coronary heart disease.
康恩贝：麝香通心滴丸获批国家中药保护品种延长保护期
Zhejiang Conba Pharmaceutical: The Musk Attentive Pill has been approved for an extended protection period for national traditional Chinese medicine.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated